Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(4-amino-5h-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
2. Bcx-4430
3. Bcx4430
4. Imma Cpd
5. Immucillin A
6. Immucillin-a
1. 249503-25-1
2. Immucillin A
3. Immucillin-a
4. Bcx4430
5. Bcx-4430
6. Bcx 4430 Free Base
7. (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
8. Olf97f86a7
9. Bcx4430 Freebase
10. Imma Cpd
11. 3,4-pyrrolidinediol,2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-2s,3s,4r,5r
12. Bcx4430 (freebase)
13. Unii-olf97f86a7
14. (2s,3s,4r,5r)-2-{4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl}-5-(hydroxymethyl)pyrrolidine-3,4-diol
15. Ua2
16. Bcx4430freebase
17. Galidesivir [inn]
18. Galidesivir [who-dd]
19. Chembl1236524
20. Schembl12468816
21. Gtpl11920
22. Ex-a6295
23. Bdbm50513995
24. Hy-18649a
25. Zinc13492903
26. Cs-3779
27. Db11676
28. Ncgc00485882-01
29. Bcx-4430 Freebase;immucillin-a;galidesivir
30. P14655
31. A900809
32. (1s)-1-(9-carbaadenine-9-yl)-1,4-dideoxy-1,4-imino-d-ribitol
33. 3,4-pyrrolidinediol, 2-(4-amino-5h-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)-, (2s,3s,4r,5r)-
34. Galidesivir; Bcx4430; Bcx 4430; Bcx-4430;(2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
| Molecular Weight | 265.27 g/mol |
|---|---|
| Molecular Formula | C11H15N5O3 |
| XLogP3 | -2.1 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 265.11748936 g/mol |
| Monoisotopic Mass | 265.11748936 g/mol |
| Topological Polar Surface Area | 140 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 334 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Galidesivir is an adenosine analogue with a broad-spectrum antiviral activity against RNA viruses, including flaviviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, filoviruses, orthomyxoviruses, and picornaviruses.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Galidesivir works by binding to viral RNA polymerase where the natural nucleotide would bind, leading to the structural change in the viral enzyme due to altered electrostatic interactions. Disruption of viral RNA polymerase activity results in premature termination of the elongating RNA strand.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Galidesivir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galidesivir, including repackagers and relabelers. The FDA regulates Galidesivir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galidesivir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Galidesivir supplier is an individual or a company that provides Galidesivir active pharmaceutical ingredient (API) or Galidesivir finished formulations upon request. The Galidesivir suppliers may include Galidesivir API manufacturers, exporters, distributors and traders.
Galidesivir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Galidesivir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galidesivir GMP manufacturer or Galidesivir GMP API supplier for your needs.
A Galidesivir CoA (Certificate of Analysis) is a formal document that attests to Galidesivir's compliance with Galidesivir specifications and serves as a tool for batch-level quality control.
Galidesivir CoA mostly includes findings from lab analyses of a specific batch. For each Galidesivir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Galidesivir may be tested according to a variety of international standards, such as European Pharmacopoeia (Galidesivir EP), Galidesivir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galidesivir USP).
LOOKING FOR A SUPPLIER?
